President Trump has launched an observational cohort study to determine the long-term mortality effects of replacing the federal drug supply with ideological mandates.
President Donald Trump announced the nomination of domestic policy aide Heidi Overton to lead the Food and Drug Administration on Tuesday, effectively initiating an uncontrolled, nationwide phase-four clinical trial to determine the long-term mortality effects of handing the agency to a political loyalist.
While initial self-reported data suggests Overton plans to aggressively implement Health Secretary Robert F. Kennedy Jr.’s "Make America Healthy Again" protocol, experts caution that it is too early to draw definitive conclusions about the statistical likelihood of a measles resurgence. A peer-reviewed meta-analysis of the incoming administration's health agenda is still pending, and researchers note that the correlation between defunding vaccine oversight and entirely preventable childhood illnesses, while historically robust, requires continuous methodological review.
Overton has previously demonstrated a statistically significant hostility toward abortion rights. However, researchers at the NIH stress that a past prevalence of advocating against reproductive healthcare does not necessarily prove she will immediately ban the abortion pill mifepristone, only that she presents a highly elevated risk factor for doing so. Citing a lack of longitudinal data, a cautious editorial in a leading JAMA publication reminded practitioners to differentiate between the stated intention to dismantle the FDA's regulatory framework and the successful execution of said dismantling.
While the existing literature heavily implies that putting an ideological aide in charge of complex epidemiological data is a major risk factor for catastrophic regulatory failure, we must remember that the current sample size of RFK-aligned FDA commissioners is only N=1, which severely limits the statistical power of our panic.
Pending further data collection, the CDC has issued preliminary, heavily caveated guidance suggesting that vulnerable cohorts of the American public may want to consider enrolling in a control group located in Canada.